Evidence map›Paper›PMID 39663860›Full record

ReviewCancer science2025

Antitumor host immunity enhanced by near-infrared photoimmunotherapy.

Hiroshi Fukushima, Aki Furusawa, Ryuhei Okada, Yasuhisa Fujii, Peter L Choyke, Hisataka Kobayashi

Abstract readReview
In one paragraph

Review in Cancer science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hiroshi FukushimaMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0001-7548-1580
Aki FurusawaMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0002-1339-4219
Ryuhei OkadaMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0003-3589-5054
Yasuhisa FujiiDepartment of Urology, Institute of Science Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0002-6761-3229
Peter L ChoykeMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA.
Hisataka KobayashiMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0003-1019-4112

Funding

Cancer-cell specific therapy: photo-immunotherapyZIABC011513 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KOBAYASHI, HISATAKA · 2013 to 2025
$15.5M
CCR NIH HHS ZIA BC 011513Intramural NIH HHS ZIA BC011513
6 · The paper itself

Abstract

Near-infrared photoimmunotherapy (NIR-PIT) is a novel antitumor therapy that selectively kills cancer cells by NIR light-triggered photochemical reaction of IRDye700DX within Ab-photoabsorber conjugates (APCs). NIR-PIT induces immunogenic cell death, causing immune cell migration between the tumor and tumor-draining lymph nodes, and expanding multiclonal tumor-infiltrating CD8

Indexed as

ImmunotherapyInfrared RaysNeoplasmsPhototherapyAnimalsHumansImmune Checkpoint InhibitorsTumor MicroenvironmentImmune Checkpoint Inhibitorsantitumor host immunitycancerimmune cell migrationimmunogenic cell deathnear‐infrared photoimmunotherapy

Identifiers

PMID39663860
PMCPMC11875768

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.